MRZMライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (19 4月 2024 @ 04:03):

Stats
本日の出来高	2 180.00
平均出来高	3 479.00
時価総額	4.43M
EPS	$0 ( 2024-03-24 )
次の収益日	( $0 ) 2024-05-15
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0500
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-21	Braeden Lichti	Sell	3 815 294	Common stock
2023-12-21	Braeden Lichti	Sell	2	10% Secured Convertible Promissory Note
2023-06-29	Lichti Braeden	Sell	106 327	Common shares
2023-07-07	Lichti Braeden	Sell	97 000	Common shares
2023-08-29	Lichti Braeden	Sell	105 000	Common shares

INSIDER POWER
-65.91
Last 78 transactions
Buy: 7 913 036 \| Sell: 10 266 700

Marizyme, Inc. 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Marizyme, Inc. 財務諸表

Annual	2022
収益:	$233 485
総利益:	$179 166 (76.74 %)
EPS:	$-1.530

FY	2022
収益:	$233 485
総利益:	$179 166 (76.74 %)
EPS:	$-1.530

FY	2021
収益:	$210 279
総利益:	$129 925 (61.79 %)
EPS:	$-0.310

FY	2020
収益:	$197 136
総利益:	$138 844 (70.43 %)
EPS:	$-0.220

Financial Reports:

No articles found.

Marizyme, Inc.

Marizyme, Inc., a life science company, engages in the development and commercialization of medical technologies business. It offers DuraGraft, a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, and other related properties. The company also develops various products using its Krillase protease-based therapeutic platform for treating complex wounds and burns, acute ischemic stroke, deep vein thrombosis, and dissolving plaque and biofilms on teeth. In addition, it focuses on developing products to mitigate the effects of ischemia reperfusion injury in other grafting and transplantation surgeries, and other indications. Further, it is involved in developing MATLOC, a point-of-care, lab-on-chip digital screening and diagnostic device platform for chronic kidney disease assessment. The company was formerly known as GBS Enterprises Incorporated. Marizyme, Inc. was incorporated in 2007 and is based in Jupiter, Florida.